about
Impaired behavioural pain responses in hph-1 mice with inherited deficiency in GTP cyclohydrolase 1 in models of inflammatory pain.Donepezil provides positive effects to patients treated with gabapentin for neuropathic pain: an exploratory study.Vendor-derived differences in injury-induced pain phenotype and pharmacology of Sprague-Dawley rats: Does it matter?Differential effects of repeated low dose treatment with the cannabinoid agonist WIN 55,212-2 in experimental models of bone cancer pain and neuropathic pain.Glutamate Transport System as a Novel Therapeutic Target in Chronic Pain: Molecular Mechanisms and Pharmacology.Low dose of donepezil improves gabapentin analgesia in the rat spared nerve injury model of neuropathic pain: single and multiple dosing studies.Pharmacy student driven detection of adverse drug reactions in the community pharmacy setting.The β-lactam clavulanic acid mediates glutamate transport-sensitive pain relief in a rat model of neuropathic pain.Intraplantar injection of tetrahydrobiopterin induces nociception in mice.Heterozygous Mutations in Gtp-Cyclohydrolase-1 Reduce Bh4 Biosynthesis but Not Pain Sensitivity.Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers.Effects of the excitatory amino acid transporter subtype 2 (EAAT-2) inducer ceftriaxone on different pain modalities in ratA Paradigm Shift Towards Patient Involvement in Medicines Development and Regulatory ScienceModification of beta-2-microglobulin in sera from patients with small cell lung cancer: evidence for involvement of a serine proteaseThe importance of genetic background on pain behaviours and pharmacological sensitivity in the rat spared serve injury model of peripheral neuropathic painEffective integration of systems biology, biomarkers, biosimulation and modelling in streamlining drug developmentThe EUFEPS workshop on institutional peer review "The ultimate tool to advance the pharmaceutical sciences?" A continuing storyExcellence in education and training advances competitiveness of the pharmaceutical industry in EuropeIdentifying Off-Label Prescriptions Through Data Mining in Danish Community Pharmacy Servers: An Exploratory Study on Desmopressin, Diclofenac, Fucidin, Mirtazapine and QuetiapinePredictive validity of pharmacologic interventions in animal models of neuropathic painCo-administered gabapentin and venlafaxine in nerve injured rats: Effect on mechanical hypersensitivity, motor function and pharmacokineticsAn Analysis of the Fixed-Dose Combinations Authorized by the European Union, 2009-2014: A Focus on Benefit-Risk and Clinical Development ConditionsThe Wider Use of Fixed-Dose Combinations Emphasizes the Need for a Global Approach to Regulatory Guideline DevelopmentBody of evidence and approaches applied in the clinical development programme of fixed-dose combinations in the European Union from 2010 to 2016Mechanical sensory threshold in Cavalier King Charles spaniels with syringomyelia-associated scratching and control dogsDemonstrating Contribution of Components of Fixed-Dose Drug Combinations Through Longitudinal Exposure-Response Analysis
P50
Q36767434-EF38B4CA-8A4F-4DED-BCE2-220F0300315AQ39216950-A165C545-6694-4FAD-9B52-875C49134675Q39224301-42ECCE3B-8EAD-4228-8CF6-3A70D76C16B4Q39963660-F3D7267E-AAC5-49E6-8E5E-43F61DEDB3CEQ40075691-032E5882-2B1C-4D06-8D68-120EF54F5CE5Q42870936-EBCF3704-08A1-4591-AAA5-35E368B28D5FQ44299873-B65C76CD-85C2-4261-8F7A-A0F7B6856449Q47687949-238950DB-5248-40D2-97B8-BF6AEC66D245Q50456254-104D35B8-806D-4C46-BF81-0EFAFB9B6AA7Q51151814-E359DA9F-DEF8-4F81-993F-A425C0EC1B81Q54599494-F774D583-FB3A-4191-85CC-0D333604E331Q57178958-0FBBF842-93A8-46E7-AAF3-56A8F788A6BEQ60325471-DC62615F-085E-4396-BE29-1938FB9ACF2DQ70186656-3622ECB2-8211-465C-9AA4-4B860EA5F325Q80032101-1EBD325F-7D7D-4AC8-893D-E26D6192B413Q80098674-D8FBE6E2-FDAE-46E4-8D99-F1AF6BF6A3CEQ81963391-432A4EDC-1F22-44E4-9BF1-C9EB9AC409E7Q84587312-D46848A7-7F71-4490-B309-D7480024EE3EQ88164042-153DE4F4-6C77-4689-916B-FB219BB2236CQ89139902-FDB27489-1928-4646-A724-47DD39A78CA3Q89140177-9B3C7941-A22E-411F-BB5D-AA42543699D5Q91481300-F1C355CB-1E2F-4294-A6EF-8697CC9580A1Q91481367-0F6E6CDB-31AA-421E-BAB2-5ABCC0B50516Q91938980-343CAD58-E125-4E12-9DE8-088803717630Q92559779-D229B5C6-6702-44BA-968D-5C0001C9BCA5Q92985419-E8D470AE-959B-4498-B2B9-B8229F48053C
P50
description
researcher ORCID ID = 0000-0002-1085-8444
@en
name
Ole Jannik Bjerrum
@ast
Ole Jannik Bjerrum
@en
Ole Jannik Bjerrum
@es
Ole Jannik Bjerrum
@nl
type
label
Ole Jannik Bjerrum
@ast
Ole Jannik Bjerrum
@en
Ole Jannik Bjerrum
@es
Ole Jannik Bjerrum
@nl
prefLabel
Ole Jannik Bjerrum
@ast
Ole Jannik Bjerrum
@en
Ole Jannik Bjerrum
@es
Ole Jannik Bjerrum
@nl
P1153
7006962188
P31
P496
0000-0002-1085-8444